To read more about the VALOR-HCM study, please visit cle.clinic/3vuOanJ or • Clinical Trial Shows D...
Presented at ACC as a Late-Breaking Clinical Trial, VALOR-HCM explores Mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive hypertrophic cardiomyopathy. Dr. Steven Nissen and Dr. Milind Desai, principal investigator, discuss the purpose, patient selection, and findings of the VALOR-HCM trial.
To learn more about our Cleveland Clinic heart experts, please visit
Steven Nissen, MD, Chief Academic Officer - cle.clinic/2HkPhMG
Milind Desai, MD, MBA, Director of Center for Hypertrophic Cardiomyopathy - cle.clinic/2XvWi51
▶Share this video with others: • VALOR-HCM Shows Promis...
▶Subscribe to learn more about Cleveland Clinic:
kzfaq.info...
#ClevelandClinic #ConsultQD #valorhcm